Baker Brothers Advisors - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Baker Brothers Advisors ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2022$14,449,000
-6.4%
735,716
-11.1%
0.10%
+8.0%
Q2 2022$15,433,000
-15.0%
827,4800.0%0.09%
-15.4%
Q1 2022$18,163,000
-22.7%
827,4800.0%0.10%
-8.8%
Q4 2021$23,509,000
+21.3%
827,480
-10.1%
0.11%
+34.1%
Q3 2021$19,380,000
+11.7%
920,6560.0%0.08%
+11.8%
Q2 2021$17,354,000
+84.2%
920,656
+49.3%
0.08%
+85.4%
Q1 2021$9,420,000
+8.3%
616,5200.0%0.04%
+24.2%
Q4 2020$8,699,000
+83.6%
616,520
+103.9%
0.03%
+73.7%
Q3 2020$4,737,000
-14.9%
302,320
-4.9%
0.02%
-24.0%
Q2 2020$5,569,000
+116.4%
317,857
+81.6%
0.02%
+56.2%
Q1 2020$2,573,000
-41.4%
175,0000.0%0.02%
-30.4%
Q4 2019$4,391,000
+66.8%
175,0000.0%0.02%
+27.8%
Q3 2019$2,632,000
-20.8%
175,000
+31.6%
0.02%
-21.7%
Q2 2019$3,325,000
+11.3%
132,985
+1.3%
0.02%
+21.1%
Q1 2019$2,987,000
-24.1%
131,2500.0%0.02%
-40.6%
Q4 2018$3,936,000
+4.7%
131,2500.0%0.03%
+28.0%
Q3 2018$3,760,000131,2500.02%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Saturn V Capital Management LP 1,126,579$33,504,45914.02%
New Leaf Venture Partners, L.L.C. 141,000$4,193,3405.38%
First Light Asset Management, LLC 1,583,329$47,088,2044.47%
Paradigm Biocapital Advisors LP 2,178,737$64,795,6384.40%
Bain Capital Life Sciences Investors, LLC 1,275,552$37,934,9164.24%
Altium Capital Management LP 262,000$7,791,8804.06%
5AM Venture Management, LLC 462,286$13,748,3863.96%
MPM BioImpact LLC 479,053$14,247,0363.80%
Affinity Asset Advisors, LLC 450,000$13,383,0003.76%
Opaleye Management Inc. 370,000$11,003,8003.58%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders